Skip to content


Blenrep (mafodotin) is a small molecule pharmaceutical. Mafodotin was first approved as Blenrep on 2020-08-25. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.
Trade Name Blenrep
Common Name Mafodotin
Indication multiple myeloma
Drug Class Synthetic analogs of the dolastatin series
Get full access now